Keep pulling the thread on Viking Therapeutics.
The market valuation of Viking Therapeutics increased from approximately $700 million one year prior to over $9 billion as of February 29, 2024.
As of late February 2024, approximately 30 PIPE (Private Investment in Public Equity) transactions in the biotech sector have raised a cumulative total of more than $4 billion for the year.
A key feature of 'wall-crossed' PIPE transactions in biotech is the sharing of material non-public information, such as clinical trial results, with select investors before the information is made public.
The XBI biotech index has increased by 14% year-to-date as of February 29, 2024.
The XBI biotech index rose 6% on a single Monday in February 2024.
The rise in biotech stocks during the fourth quarter of 2023 was primarily driven by macroeconomic factors, such as expectations of an end to rate hikes and potential interest rate reductions in 2024.
The outperformance of biotech stocks in February 2024 was driven by company-specific positive data rather than broader macroeconomic trends.
The recent rally in the biotech sector has occurred largely in the absence of major merger and acquisition (M&A) announcements.
Viking Therapeutics reported positive data for an early-stage obesity drug candidate whose efficacy appears to be in the same range as Eli Lilly's Zepbound.
Approximately 20% of obesity treatments currently in development are also being investigated for the treatment of the fatty liver disease MASH.
Zeeland Pharma and Boehringer Ingelheim announced a Phase 2 clinical trial success for a drug candidate in MASH.
A drug being developed by Zeeland Pharma and Boehringer Ingelheim may have an impact on liver fibrosis in MASH patients, a feature not seen with other drugs in the class.